Sign in
Taking peoplePhase 2

Tests datopotamab deruxtecan in breast cancer that has spread to the brain

Tests datopotamab deruxtecan in adults with triple negative breast cancer and brain spread.

Key facts

Who runs it
Medical University Of Vienna
Where
Dublin 4, IrelandSee the siteAlso in 1 other country, 1 site
Registry title
Phase II Study of daTopotamab-derUXtecan (Dato-DXd; DS-1026a) in triple-negative brEast cancer patients with newly Diagnosed or prOgressing brain metastases
Status
Recruiting
Phase
Phase 2
People taking part
26 people, planned
Started
23 May 2023
Expected to end
16 Feb 2028
Type of study
Interventional
Record updated
23 January 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with triple-negative breast cancer and new or growing brain metastases. It tests whether Dato-DXd can shrink the brain tumours.

Age
18 years or older
Sex
Men and women can join.
Disease stage
Triple-negative breast cancer with brain metastases that are newly found and untreated, or growing after earlier local treatment. Disease must be measurable (RANO-BM criteria). No need for immediate local treatment. Leptomeningeal disease type II is allowed.
Earlier treatment
Must have had a PD-1 or PD-L1 inhibitor before. Must not have had sacituzumab Govitecan or another Trop2-directed ADC. Waiting time needed after surgery, radiation, chemotherapy and antibody treatment.
Biomarker or test result
Triple-negative disease (histologically confirmed breast cancer).

Main reasons for not taking part

  • Known allergy to Dato-DXd or its ingredients
  • Another cancer in the last 3 years (some skin and cervical cancers excepted)
  • History of ILD/pneumonitis needing steroids, or serious lung problems
  • Active hepatitis B or C, or HIV that is not well controlled
  • Pregnant or breastfeeding

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • Histologically confirmed breast cancer • Triple-negative disease • Newly diagnosed untreated brain metastases or brain metastases progressing after prior local therapy • Measurable disease (RANO-BM criteria) • No indication for immediate local treatment • Accompanying type II leptomeningeal disease allowed (suspected LMD by clinical findings and neuroimaging) • KPS ≥70%, ECOG ≤2 • Indication for systemic anti-cancer treatment • Prior exposure to PD-1, PD-L1 inhibitors • Life expectancy of at least 3 months • Age ≥18 years • Patient must be able to tolerate therapy • Adequate bone-marrow, liver and kidney function • Adequate treatment washout period before enrolment, defined as: • Major Surgery: ≥3 weeks • Radiation therapy to the chest: ≥4 weeks • Palliative radiation therapy to other areas: ≥2 weeks • Chemotherapy, small-molecule targeted agents: ≥3 weeks • Antibody-based treatment: ≥4 weeks (concurrent therapy with denosumab allowed) • Patient must be capable of understanding the purpose of the study and have given written informed consent
  • No prior treatment with sacituzumab Govitecan or other Trop2-directed ADCs

Who cannot take part

  • Prior treatment with sacituzumab Govitecan or other Trop2-directed ADCs
  • Known hypersensitivity to Dato-DXd or any of the drug components • Use of any investigational agent within 28 days prior to initiation of treatment • History of malignancies other than squamous cell carcinoma, basal cell carcinoma of the skin or carcinoma in situ of the cervix within the last 3 years including contralateral breast cancer • Other anticancer therapy • Concomitant radiotherapy • A history of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant and adversely affecting compliance to study drugs • Clinically significant cardiac d • Inadequate bone marrow function at baseline prior to study entry: • Inadequate kidney function • Subjects who have current active hepatic or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic liver disease per investigator assessment) including active or uncontrolled infections with hepatitis B and C • Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesse • Has a history of non-infectious ILD/pneumonitis that required steroids, • Subjects with bronchopulmonary disorders who require intermittent use of bronchodilators (such as albuterol) will not be excluded from this study • Patients with active opportunistic infections • Known human immunodeficiency virus (HIV) infection that is not well controlled. • Pregnant or lactating women. Women with childbearing potential must have a negative pregnancy test at screening • Women with childbearing potential, including women whose last menstrual period was less than one year prior to screening, unable or unwilling to use adequate contraception from study start to one year after the last dose of protocol therapy. Acceptable contraception methods included the application of an intrauterine device, barrier method or total abstinence • Male subjects unable or unwilling to use adequate contraception methods • Patients with known substance abuse or any other medical conditions such as clinically significant cardiac or psychological conditions, that may, in the opinion of the investigator, interfere with the subject's participation in the clinical study or evaluation of the clinical study results • Patients requiring concomitant use of chronic systemic (IV or oral) corticosteroids at doses higher than 8 mg dexamethasone per day o • Patients with significant corneal disease

Where in Ireland

Also in 1 other country, 1 site

  • St Vincent's University HospitalDublin 4, IrelandNot yet recruiting

About the trial

What the trial wants to find out

To evaluate the ability of Dato-DXd to induce objective CNS responses in patients with TNBC and newly diagnosed or progressive brain metastases.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Phase II Study of daTopotamab-derUXtecan (Dato-DXd; DS-1026a) in triple-negative brEast cancer patients with newly Diagnosed or prOgressing brain metastases
Plain-language title
Tests datopotamab deruxtecan in breast cancer that has spread to the brainGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
23 January 2026